PI Industries Ltd (PIIND) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- PI Industries reported Q1 FY26 performance broadly in line with their H2-weighted plan.
- The company experienced a decline in exports due to customer inventory adjustments, but new product growth remained strong at 46% YoY.
- Domestic business grew by 6% YoY, driven by a positive Kharif season, but impacted by regulatory disruptions in the biologicals segment.
- The pharma business saw substantial growth of 187% YoY, fueled by new business inquiries and investments in the CRDMO platform.
- PI Industries filed the first registration for their indigenously developed bio-insecticide, Pioxon Liprol, marking a significant milestone in their innovation journey.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.